Generic Name and Formulations:
Alcaftadine 0.25%; oph soln; contains benzalkonium chloride.
Indications for LASTACAFT:
Prevention of ocular itching associated with allergic conjunctivitis.
Adults and Children:
<2yrs: not established. ≥2yrs: 1 drop in each eye once daily.
Contact lenses (remove; may reinsert 10 mins after administration, if eye is not red). Pregnancy (Cat.B). Nursing mothers.
H1 histamine receptor antagonist.
Ocular effects (eg, irritation, burning/stinging, redness, pruritus), nasopharyngitis, headache.
Clinical Pain Advisor Articles
- Cannabis Use High in Migraine
- Sustained-Release Sodium Nitrite for Diabetic Neuropathic Pain Not Associated With Headaches
- Restless Leg Syndrome, Fibromyalgia, and Depression Frequent in Migraine
- Percutaneous Electrolysis May Be Useful Adjunct for Subacromial Pain Syndrome
- Treatment for Opioid Use Disorder Associated With Reduced Risk for Opioid-Related Deaths
- Recommendations for Perioperative Pain Management in Patients With Opioid Tolerance
- Vertebroplasty Comparable With Placebo for Acute Vertebral Compression Fractures
- Capsaicin 8% Patch May Be Effective in Neuropathic Pain
- Detox vs Medication-Assisted Treatment for Opioid Use Disorder in Pregnancy: Expert Roundtable
- Prior Authorization Policy May Help Reduce Long-Acting Opioid Use
- Deaths After Nonfatal Opioid Overdose: Causes and Risk Factors
- Targeted Educational Intervention Helped Reduce Opioid Exposure in Adult Inpatients
- Systematic Cross-Checking May Reduce Medical Errors in Emergency Departments
- Corticosteroid Plus Lidocaine Injections Do Not Alleviate Pain in Central Lumbar Spinal Stenosis
- Tofacitinib May Effectively Alleviate Pain in RA, Psoriatic Arthritis, and Ankylosing Spondylitis